The Role of Radioactive Iodine Therapy in Papillary Thyroid Cancer: an Observational Study Based on SEER

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2018 Jun 29

PMID 29950860

Citations 16

Authors

Jianing Tang

Deguang Kong

Qiuxia Cui

Kun Wang

Dan Zhang

Xing Liao

Yan Gong

Gaosong Wu

Affiliations

Soon will be listed here.

Abstract

Background: Papillary thyroid cancer (PTC) is a common endocrine malignancy with relatively good prognosis. Radioactive iodine (RAI) is considered effective for patients with total or nearly total thyroidectomy, but the beneficial effects of RAI are still controversial.

Materials And Methods: To determine whether RAI therapy could improve the survival rates of PTC patients, we conducted a retrospective analysis using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. Disease-specific survival (DSS) was obtained using multivariate Cox proportional hazard regressions.

Results: DSS was improved by RAI ablation in patients with tumor >2 cm, age >45 years and gross extrathyroidal or lymph node metastasis. In a further analysis, RAI therapy did not improve the DSS in patients with tumor <2 cm except those with distant metastasis. For patients with tumor >2 cm, those involving gross extrathyroidal extension, age >45 years or disease in the lymph nodes, DSS was improved after RAI therapy. Patients with distant metastasis always benefited from RAI ablation.

Conclusion: RAI ablation should be recommended to patients with tumor <2 cm and distant metastasis or patients with tumor >2 cm and one of the following risk factors: gross extrathyroidal extension, age >45 years, lymph node and distant metastases.

Citing Articles

Oldie but Goldie: The Fundamental Role of Radioiodine in the Management of Thyroid Cancer.

Campenni A, Siracusa M, Ruggeri R J Clin Med. 2024; 13(21).

PMID: 39518539 PMC: 11546874. DOI: 10.3390/jcm13216400.

Correlation between gene mutations and clinical characteristics in papillary thyroid cancer: a retrospective analysis of BRAF mutations and RET rearrangements.

Uno D, Endo K, Yoshikawa T, Hirai N, Kobayashi E, Nakanishi Y Thyroid Res. 2024; 17(1):21.

PMID: 39278941 PMC: 11404047. DOI: 10.1186/s13044-024-00209-4.

Lymph Node Metastasis in Papillary Thyroid Carcinoma, A Study of BRAF V600E and TERT Promoter Mutations.

Soeratman A, Kartini D, Andinata B, Harahap A, Sudarsono N Asian Pac J Cancer Prev. 2024; 25(6):2043-2049.

PMID: 38918666 PMC: 11382857. DOI: 10.31557/APJCP.2024.25.6.2043.

Comparative analysis through propensity score matching in thyroid cancer: unveiling the impact of multiple malignancies.

Al-Ibraheem A, Abdlkadir A, Al-Adhami D, Lopci E, Al-Omari A, Al-Masri M Front Endocrinol (Lausanne). 2024; 15:1366935.

PMID: 38894738 PMC: 11184125. DOI: 10.3389/fendo.2024.1366935.

Papillary Thyroid Carcinoma With Lymphoepithelial Features and Lacking Association With Epstein-Barr Virus (EBV): A Rare Case.

Bendari A, Geetha S, Al-Refai R, Zhong X, Sham S, Harshan M Cureus. 2024; 16(2):e55222.

PMID: 38558705 PMC: 10981357. DOI: 10.7759/cureus.55222.

References

Lang B, Wong K, Wan K . Postablation stimulated thyroglobulin level is an important predictor of biochemical complete remission after reoperative cervical neck dissection in persistent/recurrent papillary thyroid carcinoma. Ann Surg Oncol. 2012; 20(2):653-9. PMC: 3560939. DOI: 10.1245/s10434-012-2624-8. View

Grebe S, Hay I . Follicular cell-derived thyroid carcinomas. Cancer Treat Res. 1997; 89:91-140. DOI: 10.1007/978-1-4615-6355-6_6. View

Tala H, Tuttle R . Contemporary post surgical management of differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010; 22(6):419-29. DOI: 10.1016/j.clon.2010.04.005. View

Han S, Park W, Jang J, Min S, Ryu J, Song J . BRAF mutation may predict higher necessity of postoperative radioactive iodine ablation in papillary thyroid cancer. Ann Surg Treat Res. 2014; 87(4):174-9. PMC: 4196434. DOI: 10.4174/astr.2014.87.4.174. View

Tsang R, Brierley J, Simpson W, Panzarella T, Gospodarowicz M, Sutcliffe S . The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer. 1998; 82(2):375-88. View

Lim H, Devesa S, Sosa J, Check D, Kitahara C . Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA. 2017; 317(13):1338-1348. PMC: 8216772. DOI: 10.1001/jama.2017.2719. View

Cooper D, Doherty G, Haugen B, Hauger B, Kloos R, Lee S . Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19(11):1167-214. DOI: 10.1089/thy.2009.0110. View

Wartofsky L, Van Nostrand D . Radioiodine treatment of well-differentiated thyroid cancer. Endocrine. 2012; 42(3):506-13. DOI: 10.1007/s12020-012-9729-5. View

Lee N, Tuttle M . The role of external beam radiotherapy in the treatment of papillary thyroid cancer. Endocr Relat Cancer. 2006; 13(4):971-7. DOI: 10.1677/ERC-06-0039. View

10.

Grigsby P, Reddy R, Moley J, Hall B . Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment. Surgery. 2006; 140(6):1043-7. DOI: 10.1016/j.surg.2006.08.007. View

11.

Meier D, Brill D, Becker D, Clarke S, Silberstein E, Royal H . Procedure guideline for therapy of thyroid disease with (131)iodine. J Nucl Med. 2002; 43(6):856-61. View

12.

Luster M, Clarke S, Dietlein M, Lassmann M, Lind P, Oyen W . Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008; 35(10):1941-59. DOI: 10.1007/s00259-008-0883-1. View

13.

Zaydfudim V, Feurer I, Griffin M, Phay J . The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery. 2008; 144(6):1070-7. DOI: 10.1016/j.surg.2008.08.034. View

14.

Schneider D, Elfenbein D, Lloyd R, Chen H, Sippel R . Lymph node metastases do not impact survival in follicular variant papillary thyroid cancer. Ann Surg Oncol. 2014; 22(1):158-63. PMC: 4275358. DOI: 10.1245/s10434-014-3964-3. View

15.

Chow S, Law S, Mendenhall W, Au S, Chan P, Leung T . Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys. 2002; 52(3):784-95. DOI: 10.1016/s0360-3016(01)02686-4. View

16.

Mazzaferri E, Jhiang S . Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994; 97(5):418-28. DOI: 10.1016/0002-9343(94)90321-2. View

17.

Pacini F, Schlumberger M, Dralle H, Elisei R, Smit J, Wiersinga W . European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006; 154(6):787-803. DOI: 10.1530/eje.1.02158. View

18.

Hay I, Grant C, Van Heerden J, Goellner J, Ebersold J, Bergstralh E . Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery. 1992; 112(6):1139-46; discussion 1146-7. View

19.

Podnos Y, Smith D, Wagman L, Ellenhorn J . Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. J Surg Oncol. 2007; 96(1):3-7. DOI: 10.1002/jso.20656. View

20.

Cady B, SEDGWICK C, MEISSNER W, Wool M, SALZMAN F, Werber J . Risk factor analysis in differentiated thyroid cancer. Cancer. 1979; 43(3):810-20. DOI: 10.1002/1097-0142(197903)43:3<810::aid-cncr2820430306>3.0.co;2-b. View